Login to Your Account



ODAC Votes In Favor Of Expanded Tarceva Label

By Aaron Lorenzo


Wednesday, September 14, 2005
BETHESDA, Md. - Panel members recommended approving Tarceva (erlotinib) for pancreatic cancer, siding with the drug's developers and against criticism from the FDA. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription